First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

R. Descourt, Laurent Greillier, M. Pérol, Charles Ricordel, J.B. Auliac, L. Falchero, Radj Gervais, Rémi Veillon, S. Vieillot, Florian Guisier, M. Marcq, G. Justeau, L. Bigay-Gamé, Marie Bernardi, P. Fournel, H. Doubre, J. Pinsolle, Karim Amrane, C. Chouaïd, C. Decroisette